This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Breilh, D.
Right arrow Articles by Saux, M.-C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Breilh, D.
Right arrow Articles by Saux, M.-C.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, October 1999, p. 2409-2411, Vol. 43, No. 10
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.

Pharmacokinetics of Isepamicin during Continuous Venovenous Hemodiafiltration

Dominique Breilh,1 Bernard Allaouchiche,2,* Hélène Jaumain,3 Paul Boulétreau,3 Dominique Chassard,2 Isabelle Malbec,1 Dominique Ducint,1 and Marie-Claude Saux1

Clinical Pharmacokinetic Laboratory, Haut-Lévêque Hospital, University of Bordeaux II, Bordeaux,1 and Department of Intensive Care, Hôtel Dieu Hospital,2 and Department of Intensive Care, Edouard Herriot Hospital,3 Lyon, France

Received 31 July 1998/Returned for modification 26 December 1998/Accepted 4 August 1999

The objective of this study was to analyze the pharmacokinetics of isepamicin during continuous venovenous hemodiafiltration. Six patients received 15 mg of isepamicin per kg of body weight. The mean isepamicin concentration peak in serum was 62.88 ± 18.20 mg/liter 0.5 h after the infusion. The elimination half-life was 7.91 ± 0.83 h. The mean total body clearance was 1.75 ± 0.28 liters/h, and dialysate outlet (DO) clearance was 2.76 ± 0.59 liters/h. The mean volume of distribution was 19.83 ± 2.95 liters. The elimination half-life, DO clearance, and volume of distribution were almost constant. In this group of patients, the initial dosage of 15 mg/kg appeared to be adequate, but the dosage interval should be determined by monitoring residual isepamicin concentrations in plasma.

* Corresponding author. Mailing address: Intensive Care Unit, Hôpital de l'Hôtel Dieu, 1, place de l'Hôpital, 69288 Lyon Cedex, France. Phone: (33) 472 413 167. Fax: (33) 472 431 135. E-mail: allaouch{at}univ-lyon1.fr.

Antimicrobial Agents and Chemotherapy, October 1999, p. 2409-2411, Vol. 43, No. 10
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Syka, M., Markantonis, S. L., Mathas, C., Maggina, N. (2005). A Pilot Study of Netilmicin Pharmacokinetics During Continuous Venovenous Hemodiafiltration. J Clin Pharmacol 45: 477-481 [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»